Glenmark [GLENMARK] vs Lupin [LUPIN] Detailed Stock Comparison

Glenmark Pharmaceuticals Ltd.

NSE
Loading...

Lupin Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Glenmark Pharmaceuticals Ltd. wins in 6 metrics, Lupin Ltd. wins in 14 metrics, with 0 ties. Lupin Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Glenmark Pharmaceuticals Ltd. Lupin Ltd. Better
P/E Ratio (TTM) 59.35 22.74 Lupin Ltd.
Price-to-Book Ratio 6.60 5.37 Lupin Ltd.
Debt-to-Equity Ratio 12.78 31.51 Glenmark Pharmaceuticals Ltd.
PEG Ratio 3.73 0.60 Lupin Ltd.
EV/EBITDA 15.27 15.38 Glenmark Pharmaceuticals Ltd.
Profit Margin (TTM) 6.45% 17.76% Lupin Ltd.
Operating Margin (TTM) 18.34% 26.46% Lupin Ltd.
EBITDA Margin (TTM) 18.34% 26.46% Lupin Ltd.
Return on Equity 11.83% 18.98% Lupin Ltd.
Return on Assets (TTM) 6.52% 11.24% Lupin Ltd.
Free Cash Flow (TTM) $-15.77B $13.18B Lupin Ltd.
Dividend Yield 0.25% 0.62% Lupin Ltd.
1-Year Return 30.18% 14.69% Glenmark Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 3.83 4.03 Glenmark Pharmaceuticals Ltd.
Enterprise Value $615.44B $1,054.33B Lupin Ltd.
EV/Revenue Ratio 3.73 4.03 Glenmark Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 66.69% 73.55% Lupin Ltd.
Revenue per Share (TTM) $585 $573 Glenmark Pharmaceuticals Ltd.
Earnings per Share (Diluted) $37.74 $101.47 Lupin Ltd.
Beta (Stock Volatility) 0.29 0.28 Lupin Ltd.

Glenmark Pharmaceuticals Ltd. vs Lupin Ltd. Stock Performance Analysis

Loading Price Chart...

GLENMARK
LUPIN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Glenmark Pharmaceuticals Ltd.-0.79%-0.65%-7.28%-0.86%8.61%6.44%
Lupin Ltd.-0.88%0.83%-0.14%-0.76%8.63%8.10%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Glenmark Pharmaceuticals Ltd.30.18%238.36%239.44%186.23%606.58%3,294.97%
Lupin Ltd.14.69%176.15%98.45%56.65%418.49%2,332.69%

Performance & Financial Health Analysis: Glenmark Pharmaceuticals Ltd. vs Lupin Ltd.

MetricGLENMARKLUPIN
Market Information
Market Cap i₹662.58B₹1.07T
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i495,3371,119,327
90 Day Avg. Volume i640,5021,057,063
Last Close₹2,156.60₹2,273.10
52 Week Range₹1,625.00 - ₹2,474.00₹1,836.80 - ₹2,494.00
% from 52W High-12.83%-8.86%
All-Time High₹2,471.20 (Apr 29, 2026)₹2,459.00 (May 06, 2026)
% from All-Time High-12.73%-7.56%
Growth Metrics
Quarterly Revenue Growth0.15%0.24%
Quarterly Earnings Growth0.16%0.38%
Financial Health
Profit Margin (TTM) i0.06%0.18%
Operating Margin (TTM) i0.18%0.26%
Return on Equity (TTM) i0.12%0.19%
Debt to Equity (MRQ) i12.7831.51
Cash & Liquidity
Book Value per Share (MRQ)₹339.57₹429.87
Cash per Share (MRQ)₹95.34₹137.55
Operating Cash Flow (TTM) i₹2.11B₹28.04B
Levered Free Cash Flow (TTM) i₹10.47B₹32.82B
Dividends
Last 12-Month Dividend Yield i0.25%0.62%
Last 12-Month Dividend i₹5.00₹12.00

Valuation & Enterprise Metrics Analysis: Glenmark Pharmaceuticals Ltd. vs Lupin Ltd.

MetricGLENMARK (Apr 24, 2026)LUPIN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i59.3522.74
Forward P/E i27.9823.46
PEG Ratio i3.730.60
Price to Sales (TTM) i3.834.03
Price to Book (MRQ) i6.605.37
Market Capitalization
Market Capitalization i₹662.58B₹1.07T
Enterprise Value i₹615.44B₹1.05T
Enterprise Value Metrics
Enterprise to Revenue i3.734.03
Enterprise to EBITDA i15.2715.38
Risk & Other Metrics
Beta i0.290.28
Book Value per Share (MRQ) i₹339.57₹429.87

Financial Statements Comparison: Glenmark Pharmaceuticals Ltd. vs Lupin Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLENMARK (2025)LUPIN (2025)
Revenue/Sales i131.46B221.92B
Cost of Goods Sold i47.57B74.56B
COGS % of Revenue i36.2%33.6%
Gross Profit i83.88B147.36B
Gross Margin i63.8%66.4%
Research & Development iN/AN/A
Operating Income (EBIT) i18.68B43.45B
Operating Margin i14.2%19.6%
EBITDA i24.68B56.45B
EBITDA Margin i18.8%25.4%
Pre-Tax Income i13.99B40.15B
Pre-Tax Income % of Revenue i10.6%18.1%
Income Tax i3.52B7.09B
Income Tax % of Revenue i2.7%3.2%
Net Income (Profit) i10.47B33.06B
Profit Margin i8.0%14.9%

Balance Sheet & Liquidity Metrics

MetricGLENMARK (2025)LUPIN (2025)
Cash & Equivalents i16.76B19.31B
Total Current Assets i92.95B167.99B
Total Current Assets % of Revenue i70.7%75.7%
Total Current Liabilities i59.67B89.61B
Total Current Liabilities % of Revenue i45.4%40.4%
Long-Term Debt i6.99B20.31B
Long-Term Debt % of Revenue i5.3%9.1%
Total Shareholders Equity i88.49B172.94B
Retained Earnings i87.99B140.71B
Retained Earnings % of Revenue i66.9%63.4%
Property, Plant & Equipment i33.19B84.20M

Cash Flow Statement Comparison

MetricGLENMARK (2025)LUPIN (2025)
Operating Cash Flow i2.11B28.04B
Operating Cash Flow % of Revenue i1.6%12.6%
Capital Expenditures i-7.47B-16.53B
Free Cash Flow i-15.77B13.18B
FCF Margin i-12.0%5.9%
Debt Repayment i-1.41B0
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLENMARKLUPIN
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i282.20M457.18M
Float Shares i141.58M241.86M
% Held by Insiders i48.96%47.03%
% Held by Institutions i26.61%34.14%
% Held by Public i24.43%18.83%

Dividend Analysis & Yield Comparison: Glenmark Pharmaceuticals Ltd. vs Lupin Ltd.

MetricGLENMARKLUPIN
Last 12-Month Dividend i₹5.00₹12.00
Last 12-Month Dividend Yield i0.25%0.62%
3-Year Avg Annual Dividend i₹3.33₹8.00
3-Year Avg Dividend Yield i0.18%0.50%
3-Year Total Dividends i₹10.00₹24.00
Ex-Dividend DateOct 03, 2025Jul 25, 2025